Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Aptose Bioscns (APTO)

Aptose Bioscns (APTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,455
  • Shares Outstanding, K 18,109
  • Annual Sales, $ 0 K
  • Annual Income, $ -51,210 K
  • 60-Month Beta 1.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade APTO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -6.20
  • Most Recent Earnings $-0.73 on 05/14/24
  • Next Earnings Date 08/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.58
  • Number of Estimates 2
  • High Estimate -0.58
  • Low Estimate -0.59
  • Prior Year -2.27
  • Growth Rate Est. (year over year) +74.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7101 +6.97%
on 06/25/24
1.0800 -29.67%
on 06/13/24
-0.2064 (-21.37%)
since 06/03/24
3-Month
0.7101 +6.97%
on 06/25/24
1.5600 -51.31%
on 04/04/24
-0.6804 (-47.25%)
since 04/03/24
52-Week
0.7101 +6.97%
on 06/25/24
5.1000 -85.11%
on 08/16/23
-3.8204 (-83.41%)
since 07/03/23

Most Recent Stories

More News
Aptose Reports Results for the Second Quarter 2022

─ HM43239 Preliminary Response Rate of 43% Among R/R AML Patients with FLT3 Mutations Who Failed Prior Therapy with FLT3 inhibitors ─ ─ HM43239 Complete...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference

SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022

SAN DIEGO and TORONTO, July 19, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results ...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose Presents Highlights from Corporate Update and KOL Event

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3 New “G3” Formulation of Luxeptinib Demonstrates Encouraging PK Results ...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose Biosciences Announces Results of Annual Meeting of Shareholders

SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose to Provide Program Updates at KOL Webinar on Thursday, June 2nd

Featuring distinguished hematology experts Brian Druker, M.D., Naval G. Daver, M.D. ...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)
Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Clinical Updates for HM43239 and Luxeptinib Poster Presentation for HM43239 is Scheduled for June 10th at EHA2022 Hybrid Congress SAN DIEGO and...

APTO : 0.7596 (+2.23%)
APS.TO : 1.00 (-2.91%)

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

3rd Resistance Point 0.8957
2nd Resistance Point 0.8529
1st Resistance Point 0.8062
Last Price 0.7596
1st Support Level 0.7167
2nd Support Level 0.6739
3rd Support Level 0.6272

See More

52-Week High 5.1000
Fibonacci 61.8% 3.4231
Fibonacci 50% 2.9051
Fibonacci 38.2% 2.3870
Last Price 0.7596
52-Week Low 0.7101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar